Nurmi-Lüthje Ilona, Lüthje Peter, Kaukonen Juha-Pekka, Kataja Matti
Department of Public Health, Hjelt Institute, University of Helsinki, PO Box 41, 00014, Helsinki, Finland,
Drugs Aging. 2015 Jun;32(6):477-86. doi: 10.1007/s40266-015-0267-8.
Several studies have shown that the mortality of elderly hip fracture patients is higher than that in the general population, and is higher in male than in female hip fracture patients.
The objective of this study was to investigate factors affecting overall mortality at a minimum of 11 years following a new hip fracture.
The sex, age, pre-fracture serum 25-hydroxyvitamin D level, American Society of Anesthesiologists physical status classification (ASA class), 1- to 12-month mortality, and 2- to 11-year mortality of hip fracture patients were collected. The use of anti-osteoporotic medication and prescribed calcium and vitamin D supplements during the first 3 post-operative years were checked. The survival of the patients was analyzed using both the Bayesian multivariate analysis and the life table method.
The mean age of females at the time of the index hip fracture was 80.5 years and of males was 73 years. The protective factors were age <80 years; ASA class 1-2; serum 25-hydroxyvitamin level ≥ 50 nmol/L; post-fracture use of calcium and vitamin D supplementation; post-fracture concomitant use of calcium and vitamin D supplementation and anti-osteoporotic drugs; and male sex. The excess mortality was higher among women than men. Survival was highest among patients with a vitamin D level of ≥ 50 nmol/L. Post-fracture concomitant use of calcium and vitamin D and anti-osteoporotic drugs was positively associated with survival.
Our results indicate a positive relationship between a sufficient pre-fracture vitamin D serum concentration (≥ 50 nmol/L) and survival, and a potential relationship between reduced mortality and the concomitant post-fracture use of prescribed calcium plus vitamin D supplementation and anti-osteoporotic medication.
多项研究表明,老年髋部骨折患者的死亡率高于普通人群,且男性髋部骨折患者的死亡率高于女性。
本研究的目的是调查影响髋部骨折后至少11年总死亡率的因素。
收集髋部骨折患者的性别、年龄、骨折前血清25-羟基维生素D水平、美国麻醉医师协会身体状况分级(ASA分级)、1至12个月的死亡率以及2至11年的死亡率。检查术后前3年抗骨质疏松药物的使用情况以及规定的钙和维生素D补充剂的使用情况。使用贝叶斯多变量分析和生命表法分析患者的生存率。
初次髋部骨折时女性的平均年龄为80.5岁,男性为73岁。保护因素包括年龄<80岁;ASA分级为1-2级;血清25-羟基维生素水平≥50 nmol/L;骨折后使用钙和维生素D补充剂;骨折后同时使用钙和维生素D补充剂及抗骨质疏松药物;以及男性性别。女性的超额死亡率高于男性。维生素D水平≥50 nmol/L的患者生存率最高。骨折后同时使用钙、维生素D和抗骨质疏松药物与生存率呈正相关。
我们的结果表明,骨折前维生素D血清浓度充足(≥50 nmol/L)与生存率之间存在正相关,骨折后同时使用规定的钙加维生素D补充剂和抗骨质疏松药物与死亡率降低之间可能存在关联。